Structured Review

ALZA non targeting dsrna
Non Targeting Dsrna, supplied by ALZA, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/non targeting dsrna/product/ALZA
Average 88 stars, based on 1 article reviews
Price from $9.99 to $1999.99
non targeting dsrna - by Bioz Stars, 2020-07
88/100 stars

Related Products / Commonly Used Together

transfection lipid
osmotic minipumps
σ sirna
raf-1 sirna

Images

Related Articles

Western Blot:

Article Title: Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA
Article Snippet: .. Raf-1 protein level in the lumbar spinal cords of naïve, animals pretreated with vehicle, Raf-1-selective siRNA mixture or non-targeting dsRNA was assessed by Western blots. .. In lumbar spinal cord extracts from naïve rats, the Raf-1-selective antibody recognized a diffuse band in the molecular weight range of 72–74 kDa ( , lanes 1 and 2). i.th Raf-1-selective siRNA pretreatment significantly reduced Raf-1 protein levels in the lumbar spinal cord tissue homogenates ( , lanes 3–8).

Transfection:

Article Title: Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA
Article Snippet: .. After 3 days of pretreatment with transfection lipid or Raf-1 siRNA or non-targeting dsRNA, osmotic minipumps (Alza, Mountain view, CA, USA) were implanted into the subcutaneous space by making a 1 cm incision on the dorsal surface of the skin. ..

other:

Article Title: Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA
Article Snippet: However, i.th Raf-1-selective siRNA pretreatment significantly attenuated the development of tactile allodynia after 6 days of sustained morphine treatment ( P < 0.05 relative to the vehicle-pretreated morphine-infused group, two-way anova , n = 6). i.th administration of a non-targeting dsRNA and saline infusion did not produce a significant alteration in the response threshold to non-noxious mechanical stimulation on day 6 ( P > 0.05 relative to the vehicle-pretreated saline-infused group, two-way anova , n = 6).

Article Title: Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA
Article Snippet: The CGRP content in animals pretreated with the non-targeting dsRNA and receiving saline was similar to the basal CGRP value in the vehicle-pretreated saline-infused animals ( P > 0.05, one-way anova , n = 4).

Article Title: Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA
Article Snippet: The effects of the siRNA treatment were presumably selective to Raf-1, because i.th pretreatment of the animals with a control, non-targeting dsRNA had no effect on pain sensitivity in either saline- or morphine-infused rats.

Article Title: Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA
Article Snippet: Intrathecal catheter implantation caused no significant change in the sensitivity of the animals towards mildly noxious heat stimulus (baseline paw withdrawal latencies were similar to the pre-infusion baseline ( P > 0.05, n = 6) ( ). i.th pretreatments with either the vehicle (21.2 ± 0.4 s), non-targeting dsRNA or the Raf-1-selective siRNA alone did not alter response thresholds in rats receiving sustained saline infusions for 7 days ( P > 0.05 relative to pre-infusion baseline, two-way anova , n = 6).

Article Title: Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA
Article Snippet: Baseline paw withdrawal thresholds were similar to the pre-infusion baseline ( P > 0.05) ( ). i.th pretreatments with either the vehicle, non-targeting dsRNA or the Raf-1-selective siRNA alone did not alter response thresholds in rats receiving sustained saline infusions for 7 days ( P > 0.05 relative to pre-infusion baseline, two-way anova ).

Article Title: Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA
Article Snippet: The CGRP content in animals pretreated with the non-targeting dsRNA and receiving morphine was similar to the vehicle-pretreated morphine-infused animals ( P < 0.01 relative to vehicle-pretreated saline group, one-way anova , n = 4) indicating that the effects mediated by Raf-1 siRNA were specific ( ).

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 88
    ALZA non targeting dsrna
    Non Targeting Dsrna, supplied by ALZA, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/non targeting dsrna/product/ALZA
    Average 88 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    non targeting dsrna - by Bioz Stars, 2020-07
    88/100 stars
      Buy from Supplier

    Image Search Results